Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)

    Supports investigator-initiated clinical trials for neurological disorders, from early exploratory studies to Phase 3 confirmatory and comparative effectiveness trials.

    Browse similar grants
    Neuroscience Research Grants 2026
    OverviewSimilar Grants
    OverviewSimilar Grants

    Funder: National Institutes of Health

    Due Dates: February 10, 2027 (New) | March 10, 2027 (Renewal/Resubmission/Revision) | June 10, 2027 (New) | July 9, 2027 (Renewal/Resubmission/Revision) | October 8, 2027 (New) | November 8, 2027 (Renewal/Resubmission/Revision) | February 10, 2028 (New) | March 10, 2028 (Renewal/Resubmission/Revision) | June 9, 2028 (New) | July 10, 2028 (Renewal/Resubmission/Revision) | October 10, 2028 (New) | November 9, 2028 (Renewal/Resubmission/Revision) | February 9, 2029 (New) | March 9, 2029 (Renewal/Resubmission/Revision; final closing)

    Funding Amounts: No budget cap; budgets must reflect project needs; up to 7 years total; no cost sharing required

    Summary: Supports investigator-initiated exploratory, confirmatory, and comparative effectiveness clinical trials of interventions for neurological disorders.

    Key Information: Clinical trials are required; applications involving foreign subawards or subcontracts are not eligible for funding.


    Description

    The National Institute of Neurological Disorders and Stroke (NINDS) supports investigator-initiated clinical trials developing interventions to prevent neurological disorders or improve their outcomes. Supported interventions include small molecules, biologics, devices, surgery, behavioral treatments, diet-based therapies, and rehabilitation. Studies addressing neurological diseases and care across the lifespan are highly encouraged.

    This opportunity supports early- and middle-phase exploratory trials, later-phase confirmatory or pivotal trials, comparative effectiveness trials, and seamless Phase 2/3 designs. Pragmatic trials with minimal changes to clinical practice and low per-participant costs are encouraged, as are rare-disease trials. The milestone-driven UG3/UH3 cooperative agreement begins with planning, start-up, and feasibility work, followed by full trial implementation only after satisfactory progress and administrative review.


    Atom

    See the full grant listing

    Sign in to view full eligibility details, sources, similar grants, and AI-powered analysis.